SIPAI HEALTH (00314.HK): adopts 2026 share award scheme, cap at 5% of issued shares, no new shares
NewTimeSpace News: On 20 November 2026, Sipai Health Technology Co., Ltd. (00314.HK) announced voluntarily that its board resolved on 20 November 2026 to adopt the 2026 Share Award Scheme to recognise the contributions of certain eligible participants and provide them with incentives to retain them to contribute to the continuing operation and development of the Group, and to attract suitable talent to drive the Group's further development.
The scheme constitutes a share scheme under Chapter 17 of the Listing Rules and is subject to the applicable disclosure requirements under Rule 17.12. Pursuant to Rule 17.01(1)(b), the scheme is proposed to be conducted and adopted with funding provided solely by existing shares and does not constitute a scheme involving the issue of new shares under Rule 17.01(1)(a); accordingly, the adoption of the scheme does not require shareholders' approval. The scheme is a single share award scheme under which no options may be granted, and will involve the purchase of existing shares of the Company by the trustee through the Stock Exchange.
On the principal terms, the scheme will remain valid for a period of ten years after the adoption date unless terminated earlier by the board. Under the scheme limit, the administrator may not further grant award shares if the aggregate number of shares to be granted would exceed 5% of the issued share capital of the Company as at the adoption date, and the number of shares granted to any single selected participant may not exceed 1% of the issued share capital of the Company in any 12-month period. In addition, unless and until the award interests are actually transferred to a selected participant on the vesting date, the selected participant shall not have any interest or right (including the right to receive dividends) in the award interests by reason of the grant, and the trustee shall abstain from exercising voting rights attached to any shares held under the trust.
- SIPAI HEALTH (00314.HK): HK$3m deal for 90% of broker
- SIPAI HEALTH (00314.HK): to sell 100% of target company to Dashenlin for RMB15 million in major transaction
- SIPAI HEALTH (00314.HK): Completion of acquisition of 100% equity interest in Jianyi Information Technology
- SIPAI HEALTH(00314.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at CNY 43.29 million, turned profitable from a loss YoY
- SIPAI HEALTH(00314.HK) closed 13.9% lower, the Hang Seng Pharmaceuticals & Biotechnology Sector saw divergent trends